Ascendis Pharma initiated with buy rating on strong growth, product launches, and upcoming milestones.

Ascendis Pharma, a biotech company specializing in rare endocrine diseases, has been initiated with a buy rating due to its transition to a commercial-stage franchise. The company's valuation is supported by high-quality revenue growth, multiple product launches including Yorvipath and Yuviwel, and reduced financing risk. Yorvipath is rapidly scaling in chronic hypoparathyroidism, while Yuviwel is set for expansion in achondroplasia. Over the next 12 to 18 months, several regulatory, clinical, and commercial milestones are expected to drive growth and support the company's self-funded strategy and platform expansion.